Three months after a coronavirus disease (COVID-19) outbreak in Kupferzell, Germany, a population-based study found no RT-PCR-positives. IgG-ELISA seropositivity with positive virus neutralisation tests was 7.7% (95% confidence interval (CI): 6.5–9.1) and 4.3% with negative neutralisation tests. We estimate 12.0% (95% CI: 10.4–14.0%) infected adults (24.5% asymptomatic), six times more than notified. Full hotspot containment confirms the effectiveness of prompt protection measures. However, 88% naïve adults are still at high COVID-19 risk.

After a large church concert on 1 March 2020 and a first detected infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on 9 March, the southern German community of Kupferzell in the federal state Baden-Württemberg faced a steep increase of SARS-CoV-2 infections. Investigations of the local health authorities showed increasing evidence of community spreading in a complex and chronologically dense pattern of travel returnees who attended a choir and trombone church concert. Wide-reaching infection prevention and local control measures were implemented starting in the week of the first case detection, followed by additional measures such as a ban on gatherings in the federal state starting mid-March. The number of SARS-CoV-2 infections peaked in March but waned in April, and there were only three cases in May (Figure). There were three deaths, aged 59, 81 and 91 years. The cumulative incidence of 1,760 per 100,000 in Kupferzell by the end of April was, at the time of the study, one of the highest in Germany. The Robert Koch Institute (RKI) set out to analyse the SARS-CoV-2 seroprevalence in a random sample of this community from 20 May to 9 June.

**CoMoLo study**

The seroepidemiological study in Kupferzell, Germany is part of the population-based corona-monitoring local (CoMoLo) study that investigates the prevalence of SARS-CoV-2 IgG antibodies and of current infections in four communities with a high case incidence. Details are provided in the study protocol [1].

A random sample of 3,534 Kupferzell residents aged 18 years and older from the mandatory population registry (68.9% of the 5,128 adult residents) was invited to take part in the study, and 2,203; (48.5% women; 18–94 years; Table 1) had venous blood sampling (Figure). These participants were 63% of those eligible. Some 2,184 had SARS-CoV-2 RT-PCR testing of throat swabs targeting the E gene and the orf1ab region of SARS-CoV-2 [2]. The Robert Koch Institute performed SARS-CoV-2-S1 IgG-ELISA (Euroimmun, Lübeck, Germany)
Figure
Notified COVID-19 cases in adults 18 years and older and flow-chart of study design, Kupferzell, Germany, March–June 2020 (n = 5,128)

n = 3,534 random population registry sample, age ≥ 18 years

Problems with the appointment/participation (n = 133); eligible but refusal (n = 133); eligible, miscellaneous reasons for non-participation (n = 46); no answer, unknown eligibility (n = 987); not eligible (n = 32)

n = 2,203 analysis sample with venous blood specimens

PCR (n = 2,184), all negative

IgG-ELISA (n = 2,203)

negative n = 2,203
indeterminate n = 40
positive n = 249

Test for neutralising antibodies

positive n = 0
positive n = 167

COVID-19: coronavirus disease;
## Table 1
Characteristics of study population, COVID-19 cases 18 years and older, Kupferzell, Germany, 20 May–9 June 2020 (n = 2,203)

|                     | n   | Weighted % | 95% CI       |
|---------------------|-----|------------|--------------|
| **Sex**             |     |            |              |
| Female              | 1,143 | 48.5       | 46.6–50.3    |
| Male                | 1,060 | 51.5       | 49.7–53.4    |
| **Age female**      |     |            |              |
| 18–34 years         | 379  | 25.1       | 22.8–27.7    |
| 35–49 years         | 279  | 23.6       | 21.2–26.3    |
| 50–64 years         | 282  | 28.5       | 25.8–31.4    |
| ≥ 65                | 203  | 22.7       | 20.1–25.5    |
| **Age male**        |     |            |              |
| 18–34 years         | 334  | 26.6       | 23.8–29.6    |
| 35–49 years         | 254  | 26.2       | 23.3–29.3    |
| 50–64 years         | 290  | 28.2       | 25.6–31.1    |
| ≥ 65                | 182  | 18.9       | 16.5–21.6    |
| **Secondary school education** | | | |
| Lower               | 670  | 42.8       | 40.3–45.3    |
| Middle              | 731  | 28.2       | 26.4–30.1    |
| Higher              | 744  | 29.0       | 26.9–31.1    |
| **Household size**  |     |            |              |
| 1 person            | 227  | 11.4       | 10.0–13.0    |
| 2 persons           | 729  | 34.3       | 31.7–36.9    |
| 3–4 persons         | 877  | 39.0       | 36.3–41.8    |
| ≥ 4 persons         | 324  | 15.3       | 13.2–17.8    |
| **Exposures**       |     |            |              |
| Working with patients| 204  | 10.0       | 8.6–11.5     |
| Working with customers| 432  | 21.3       | 19.3–23.3    |
| Travelled abroad since 1 January | 361 | 15.0 | 13.4–16.9 |
| Participated in event with ≥ 50 persons | 636 | 26.4 | 24.3–28.6 |
| **Quarantine or isolation** | | | |
| Voluntary           | 256  | 11.8       | 10.3–13.4    |
| Mandated            | 317  | 14.3       | 12.6–16.2    |
| **Self-reported health** | | | |
| Very good           | 739  | 31.6       | 29.5–33.7    |
| Good                | 1,156 | 55.2       | 52.9–57.4    |
| Moderate/bad/very bad| 247  | 13.2       | 11.7–14.9    |
| **Medical conditions** | | | |
| Self-reported COVID-19 | 50   | 2.4        | 1.8–3.2     |
| Chronic conditions* | 638  | 35.3       | 33.0–37.7    |
| **Symptoms since 1 February** | | | |
| Fever ≥ 38°C        | 209  | 9.6        | 8.3–11.1     |
| Dyspnoea, shortness of breath | 145 | 6.6 | 5.6–7.9   |
| Pneumonia           | 11   | 0.5        | 0.3–1.0      |
| Congested/running nose | 627 | 28.6 | 26.5–30.8 |
| Cough               | 549  | 25.0       | 23.0–27.1    |
| Pain when breathing | 76   | 3.5        | 2.7–4.4      |
| Sore throat         | 558  | 24.0       | 22.1–26.0    |
| Loss of smell or taste | 131 | 6.0 | 5.0–7.2 |
| No symptoms         | 1,042 | 51.2 | 48.8–53.7 |
| Mild symptoms only  | 922  | 41.8       | 39.4–44.2    |
| Moderate or severe symptoms (pneumonia, dyspnoea) | 153 | 7.0 | 5.9–8.3 |

CI: confidence interval; COVID-19: coronavirus disease.

* Lung or heart disease, diabetes, stroke, hypertension, immunodeficiency.

Complementary categories are not always shown, e.g. ‘not working with patients’ and missing values are not shown, therefore n do not always add up to the total.
and applied the thresholds provided in the manual [1]. All samples that tested SARS-CoV-2-S1-IgG-positive (ratio ≥ 1.1) or indeterminate (ratio 0.8 to < 1.1) were additionally tested for neutralising antibodies with plaque reduction neutralisation tests (prNT) [3] at the German consultant laboratory for human coronaviruses at Charité – Universitätsmedizin Berlin.

Underascertainment of SARS-CoV-2 infections was calculated as the ratio of two population proportions: the proportion of SARS-CoV-2 infections calculated from our study and the cumulative incidence of non-fatal PCR-positive cases in the adult population of Kupferzell calculated from notified cases aged 18 years and older. Proportions of IgG-positives were adjusted for sensitivity (88.3%) and specificity (99.2%) of the Euroimmun S1-SARS-CoV-2 IgG test [4], according to validity studies conducted by the Paul Ehrlich Institute. These validity studies had tested 513 pre-pandemic specimens and 222 convalescent coronavirus disease (COVID-19) patients, the vast majority (96%) at least 21 days after symptom onset (personal communication, H. Scheiblauer, 30 Sep 2020).

Statistical analyses were conducted using SAS 9.4 survey procedures. Results were weighted to the population of Kupferzell with regard to age group, sex and school education (district level). Clustering within households was taken into account.

**Ethical statement**
This study was approved by the ethics committee of the Berlin Chamber of Physicians (Berliner Ärztekammer, reference number Eth-11/20), and the data commissioner of the Robert Koch Institute. All participants gave informed consent.

**Seroprevalence**
All SARS-CoV-2 swabs taken during the study were negative in RT-PCR. The population-weighted prevalence of indeterminate IgG results was 1.9%; positive IgG results occurred with a prevalence of 11.3% or, when corrected for test performance, 12.0% (95% confidence interval (CI): 10.4–14.0) (Table 2). The lowest IgG seroprevalence in women was among the 18–34 year-olds, in men among the 35–49 year-olds. Factors associated with seropositivity were loss of smell or taste, fever ≥ 38°C, a history of travelling or attending a large event and very good self-reported health. The association of seropositivity with ‘quarantine or isolation’ is not surprising since these participants were likely to be either diagnosed COVID-19 cases or close contacts. None of the participants with indeterminate IgG had a positive prNT, i.e. neutralising antibodies. The population-weighted seroprevalence of anti-SARS-CoV-2 IgG with positive prNT was 7.7% (95% CI: 6.5–9.1).

**Cumulative incidence of SARS-CoV-2 infections**
For the cumulative incidence of SARS-CoV-2 infections, we considered current infections (in this study none because all study PCR tests were negative) and past infections. The vast majority of past infections can be identified by IgG antibodies, but not all [5]: in the subgroup of 50 participants with self-reported COVID-19 diagnosis done before the study period, only 89% (weighted percentage; 95% CI: 77.3–95.0) were IgG-positive (Table 3). The seropositivity rate in the 26 participants with self-reported COVID-19 diagnosis with mild symptoms was 87% (weighted percentage; 95% CI: 70.7–95.1) and in those with moderate-to-severe symptoms (n = 16) it was 94% (weighted percentage; 95% CI: 66.5–99.3). However, this was well taken into account by the mathematical correction for sensitivity and specificity since the corrected proportion of seropositives among these 50 participants was ca 100%. 24.5% of seropositive participants reported that they had not had any of the eight investigated symptoms since 1 February (16.8% of those with neutralising antibodies).

The underascertainment ratio comparing IgG seropositivity corrected for test performance, with the officially reported cumulative incidence was 6.1 (95% CI: 5.2–7.0). If calculated based on seropositivity of both IgG and prNT, the underascertainment ratio would be 3.9 (95% CI: 3.2–4.6).

**Discussion**
Seroepidemiological studies are key to understanding the distribution of infections in the population, despite uncertainties deriving from test performance and from the proportion of infected persons who never develop or have declining levels of antibodies [5-10].

Our results of 12% IgG-seropositive participants corrected for test performance and a proportion of 25% asymptomatic infections are in line with the results from the German high-prevalence towns Gangelt [10] and Neustadt am Rennsteig [11]. Seroepidemiological studies conducted in Germany [12] are systematically tracked by the German national public health institute (Robert Koch Institute; www.rki.de/covid-19-serostudies-germany). The cumulative incidence of infections of 15.5% in Gangelt [13] was based on RT-PCR-positive cases and on positive or indeterminate S1-ELISA-Euroimmun IgG tests, corrected for the manufacturer-provided sensitivity of 90.9% and specificity of 99.3%. From Neustadt am Rennsteig [11], a seroprevalence of 8.4% was reported, based on two of six different IgG immunoassays. Testing of a pre-existing population-based cohort in the low-prevalence area of Bönn yielded a seroprevalence of ca 1%, based on positive S1-ELISA-Euroimmun IgG tests and 0.36% with both S1-ELISA-IgG and neutralising antibodies [14]. Compared with other European areas with high COVID-19 prevalence such as Ischgl in Austria [15] or the Lodi Red Zone in Lombardy, Italy, [16] the seroprevalence in Kupferzell was still low.

The increased odds of infection after travelling abroad and after participating in larger events are in line with the outbreak history in Kupferzell. From our study and...
### Table 2A
Prevalence of SARS-CoV-2 IgG and neutralising antibodies in adults and association with sociodemographic, exposure and clinical characteristics, Kupferzell, Germany, 20 May–9 June 2020 (n = 2,203)

|                             | Prevalence of positive results in both IgG-ELISA (ratio ≥ 1.1) and prNT | IgG-ELISA-positive (ratio ≥ 1.1) | Seroprevalence: prevalence of IgG ratio ≥ 1.1 corrected for sensitivity 88.3% and specificity 99.2% | OR for being IgG-seropositive adjusted for age group and sex | Distribution among seropositives (IgG-ELISA; n = 249) |
|-----------------------------|--------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-----------------------------------------------|
|                             | n | Weighted % | 95% CI       | n | Prevalence, weighted % | 95% CI       | OR | 95% CI | Weighted % | 95% CI |
| Total                       | 167 | 7.7 | 6.5–9.1     | 249 | 11.3 | 12.0 | 10.4–14.0 | 1 | Reference | 52.1 | 46.1–58.1 |
| Female                      | 96 | 8.7 | 7.1–10.7    | 136 | 12.2 | 13.0 | 10.8–15.6 | 1 | Reference | 52.1 | 46.1–58.1 |
| Male                        | 71 | 6.7 | 5.2–8.5     | 113 | 10.5 | 11.1 | 9.0–13.6  | 0.86 | 0.67–1.12 | 47.9 | 41.9–53.9 |
| **Age female**              |                             |                                |                             |                                |                             |                             |                             |                             |                             |
| 18–34 years                 | 23 | 5.4 | 3.5–8.1     | 31 | 7.5 | 7.7 | 5.1–11.3  | 1 | Reference | 15.5 | 10.8–21.7 |
| 35–49 years                 | 20 | 7.2 | 4.6–11.1    | 39 | 14.3 | 15.4 | 11.0–21.0 | 2.04 | 1.21–3.44 | 27.6 | 20.6–36.0 |
| 50–64 years                 | 30 | 10.3 | 7.3–14.4   | 39 | 13.4 | 14.4 | 10.4–19.5 | 1.90 | 1.16–3.12 | 31.3 | 23.8–39.9 |
| ≥ 65                        | 23 | 12.0 | 8.1–17.5    | 27 | 13.7 | 14.8 | 10.0–21.2 | 1.95 | 1.12–3.42 | 25.5 | 18.2–34.5 |
| **Age male**                |                             |                                |                             |                                |                             |                             |                             |                             |                             |
| 18–34 years                 | 25 | 7.2 | 4.7–10.8    | 40 | 11.3 | 12.0 | 8.2–17.1  | 1 | Reference | 28.6 | 20.7–38.1 |
| 35–49 years                 | 6  | 2.4 | 1.0–5.3     | 11 | 4.5 | 4.3 | 1.9–8.4   | 0.37 | 0.18–0.78 | 11.2 | 6.2–19.6 |
| 50–64 years                 | 23 | 8.1 | 5.4–12.0    | 37 | 12.9 | 13.9 | 9.9–19.0  | 1.16 | 0.70–1.93 | 34.7 | 26.2–44.3 |
| ≥ 65                        | 17 | 9.8 | 6.1–15.3    | 25 | 14.2 | 15.3 | 10.2–22.5 | 1.30 | 0.73–2.32 | 25.5 | 17.6–35.4 |
| **Secondary school education** |                        |                                |                        |                                |                             |                             |                             |                             |                             |
| Lower                       | 61 | 9.0 | 6.7–11.8    | 82 | 11.6 | 12.3 | 9.7–15.5  | 0.92 | 0.62–1.35 | 43.3 | 36.5–50.3 |
| Middle                      | 58 | 8.4 | 6.2–11.2    | 86 | 12.2 | 13.0 | 10.3–16.3 | 1.10 | 0.78–1.55 | 30.0 | 24.5–36.1 |
| Higher                      | 46 | 6.0 | 4.2–8.6     | 78 | 10.6 | 11.2 | 8.6–14.4  | 1 | Reference | 26.8 | 21.5–32.8 |
| **Household size**          |                             |                                |                             |                                |                             |                             |                             |                             |                             |
| 1 person                    | 14 | 6.8 | 4.0–11.3    | 21 | 9.6 | 10.1 | 6.2–15.7  | 0.79 | 0.46–1.37 | 9.6 | 6.2–14.5 |
| 2 persons                   | 57 | 8.0 | 6.0–10.6    | 82 | 11.5 | 12.2 | 9.5–15.5  | 1 | Reference | 34.5 | 27.9–41.8 |
| 3–4 persons                 | 71 | 8.3 | 6.4–10.7    | 106 | 12.1 | 12.9 | 10.2–16.2 | 1.29 | 0.90–1.84 | 41.5 | 34.4–48.9 |
| 4+ persons                  | 23 | 6.2 | 3.7–10.2    | 37 | 10.7 | 11.4 | 7.1–17.4  | 1.13 | 0.67–1.90 | 14.4 | 9.5–21.2 |
| **Exposures**               |                             |                                |                             |                                |                             |                             |                             |                             |                             |
| Working with patients        | 23 | 12.0 | 8.0–17.6    | 30 | 14.9 | 16.1 | 10.9–23.0 | 1.41 | 0.90–2.22 | 13.3 | 9.3–18.8 |
| Working with customers       | 31 | 7.7 | 5.2–11.1    | 48 | 11.9 | 12.7 | 9.2–17.2  | 1.16 | 0.79–1.71 | 22.7 | 17.1–29.5 |
| Travelled abroad since 1 January | 31 | 8.9 | 5.8–13.5    | 58 | 16.7 | 18.1 | 13.3–24.2 | 1.93 | 1.31–2.83 | 21.9 | 16.4–28.7 |
| Event with ≥ 50 persons      | 68 | 11.9 | 9.3–15.2    | 102 | 17.2 | 18.8 | 15.0–23.1 | 2.24 | 1.63–3.07 | 39.8 | 33.2–46.7 |
| **Quarantine or isolation** |                             |                                |                             |                                |                             |                             |                             |                             |                             |
| Voluntary                    | 28 | 11.8 | 8.1–16.9    | 40 | 17.3 | 18.9 | 13.7–25.5 | 3.34 | 2.17–5.15 | 18.4 | 13.5–24.5 |
| Mandated                     | 80 | 25.4 | 20.5–31.1   | 104 | 33.1 | 36.9 | 30.4–44.1 | 8.68 | 6.00–12.5 | 42.5 | 35.4–50.0 |

CI: confidence interval; COVID-19: coronavirus disease; ELISA: enzyme-linked immunosorbent assay; Nd: not done; OR: odds ratio; prNT: plaque reduction neutralisation tests; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

a Not corrected for sensitivity and specificity.

b Lung or heart disease, diabetes, stroke, hypertension, immunodeficiency.
the three other German studies with available data, the underascertainment ratio has been smaller than 6 [11,13,14] and not 10 or higher as in a number of international locations [17]. The association of seropositivity with very good self-reported health, although not statistically significant, may be indicative of lower risk awareness and less protective behaviour. As the CoMoLo study continues in three other locations, more detailed analyses might be possible with a larger sample.

According to a recent report of IgG levels stable for up to 4 months on the one hand [18], and reports on waning of neutralising antibodies on the other hand [10,19,20], we base our estimate of the cumulative incidence of infections on IgG antibodies. However, in our subsample of 50 participants with self-reported PCR-based COVID-19 diagnoses, 11% were not IgG-positive which is in line with large population-based studies from Spain and New York State [21,22]. The cumulative incidence of infection in this subgroup, which was based on IgG corrected for sensitivity and specificity, would be 36.0% (95% CI 30.0–42.4).

### Table 2b

Prevalence of SARS-CoV-2 IgG and neutralising antibodies in adults and association with sociodemographic, exposure and clinical characteristics, Kupferzell, Germany, 20 May–9 June 2020 (n = 2,203)

| Prevalence of positive results in both IgG-ELISA (ratio ≥ 1.1) and prNT | IgG-ELISA-positive (ratio ≥ 1.1) | Seroprevalence: prevalence of IgG ratio ≥ 1.1 corrected for sensitivity 88.3% and specificity 99.2% | OR for being IgG-seropositive adjusted for age group and sex | Distribution among seropositives<sup>a</sup> (IgG-ELISA; n = 249) |
|---|---|---|---|---|
| n | Weighted % | 95% CI | n | Weighted % | 95% CI | OR | 95% CI | Weighted % | 95% CI |
| **Self-reported health** | | | | | | | | | | |
| Very good | 57 | 7.7 | 5.9–10.0 | 95 | 13.1 | 14.0 | 11.2–17.5 | 1.41 | 1.04–1.90 | 36.0 | 30.0–42.4 |
| Good | 92 | 8.1 | 6.5–10.1 | 127 | 11.1 | 11.8 | 9.6–14.3 | 1 | Reference | 53.2 | 46.8–59.6 |
| Moderate/bad/very bad | 15 | 6.3 | 3.8–10.2 | 23 | 9.4 | 9.8 | 6.2–14.9 | 0.69 | 0.42–1.14 | 10.8 | 7.2–15.8 |
| **Medical conditions** | | | | | | | | | | |
| Self-reported COVID-19 | 34 | 71.6 | 57.8–82.3 | 43 | 89.0 | 100.8 | 88.0–107.5 | 81.20 | 36.78–189.55 | 19.2 | 14.2–25.4 |
| Chronic conditions<sup>b</sup> | 53 | 8.9 | 6.7–11.7 | 71 | 11.6 | 12.3 | 9.5–15.8 | 0.78 | 0.55–1.10 | 35.4 | 28.9–42.4 |
| **Symptoms since 1 February** | | | | | | | | | | |
| Fever ≥38°C | 66 | 32.7 | 26.0–40.3 | 77 | 38.4 | 42.9 | 34.8–51.7 | 6.82 | 4.78–9.72 | 31.4 | 25.4–38.2 |
| Dyspnoea, shortness of breath | 28 | 19.4 | 13.4–27.3 | 36 | 25.8 | 28.5 | 20.6–38.2 | 2.80 | 1.81–4.33 | 14.6 | 10.5–20.1 |
| Pneumonia | Nd | 4 | Nd | Nd | Nd | Nd |
| Congested/running nose | 74 | 11.6 | 9.0–14.8 | 102 | 16.0 | 17.3 | 13.9–21.4 | 1.88 | 1.39–2.56 | 39.0 | 32.7–45.7 |
| Cough | 76 | 14.1 | 11.1–17.7 | 101 | 18.6 | 20.4 | 16.5–25.0 | 2.34 | 1.73–3.17 | 39.9 | 33.5–46.7 |
| Pain when breathing | 13 | 17.0 | 10.0–27.5 | 17 | 22.9 | 25.3 | 15.4–38.6 | 2.39 | 1.31–4.36 | 6.8 | 4.2–10.9 |
| Sore throat | 55 | 10.1 | 7.6–13.1 | 68 | 12.5 | 13.3 | 10.2–17.2 | 1.20 | 0.86–1.68 | 25.7 | 20.3–31.9 |
| Loss of smell or taste | 69 | 54.9 | 45.8–63.7 | 92 | 71.5 | 80.8 | 70.8–89.3 | 30.49 | 19.68–47.25 | 36.5 | 30.2–43.3 |
| No symptoms | 24 | 2.6 | 1.7–4.0 | 55 | 5.6 | 5.5 | 3.9–7.6 | 1 | Reference | 24.5 | 18.9–31.1 |
| Mild symptoms only | 113 | 12.6 | 10.3–15.4 | 152 | 16.6 | 18.1 | 15.0–21.6 | 3.77 | 2.62–5.42 | 59.4 | 52.4–66.1 |
| Moderate or severe symptoms (pneumonia, dyspnoea) | 29 | 19.2 | 13.3–26.8 | 39 | 26.8 | 29.7 | 21.8–39.2 | 6.30 | 3.85–10.30 | 16.1 | 11.7–21.7 |

CI: confidence interval; COVID-19: coronavirus disease; ELISA: enzyme-linked immunosorbent assay; Nd: not done; OR: odds ratio; prNT: plaque reduction neutralisation tests; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

<sup>a</sup> Not corrected for sensitivity and specificity.

<sup>b</sup> Lung or heart disease, diabetes, stroke, hypertension, immunodeficiency.

Complementary categories are not always shown, e.g. ‘not working with patients’ and missing values not shown, therefore n do not always add up to the total.
took these seronegative infected persons almost perfectly into account. However, with increasing time lag between pandemic wave and serosurveys, some additional adjustment for seroreversion may be necessary when estimating the cumulative incidence. Of note, validation studies for serological assays should have sufficient sample sizes in the healthy group, where specificity is calculated, and in the infected group, where sensitivity is calculated. In addition, they should aim for representativeness of the target population as well as clinical outcome (mild and severe COVID-19) and address cross-reactivity concerns by including subgroups of patients with other respiratory virus infections including seasonal coronavirus [23].

In Neustadt am Rennsteig, only 20 of 38 (53%; 95% CI: 37–69) previously PCR-positive persons were seropositive, which may be due to a different testing strategy (whole community screening) that tested more asymptomatic cases and to the definition of seropositivity (at least two of six different antibody tests needed to be positive). Therefore, seronegative infected persons may not have been taken into account sufficiently and the underlying cumulative incidence of infections may have been as high as 8.4 per 0.52, i.e. 16%. We therefore propose that estimates of the cumulative incidence of infections should be based not only on antibody testing but also on current and past PCR test results. Within each study, the subsample of previously PCR-positive participants, i.e. participants for whom serological and virological results are available, provides valuable information for estimating the cumulative incidence of infections. It can be used to evaluate whether correction or combination of different immunoassays, is appropriate for the specific study.

**Conclusion**

This study confirmed that even in areas with high COVID-19 prevalence, only a small proportion of the population has been infected. Therefore, ongoing protective measures are justified. Moreover, this is the second German study on a community outbreak that shows that these measures are highly effective, leading at least temporarily to full containment [11].

**Acknowledgement**

We thank the representatives of the Hohenlohe district and the community of Kupferzell: Dr. Matthias Neth, Christoph Spieles, Silke Bartholomä and Sascha Sprenger. We thank the administrative staff and data management staff of the RKI for their support. We thank everyone who contributed to the data collection in the field: the medical staff, the hotline personnel, quality assurance, the colleagues in charge with public relations and press work and the shuttle drivers. We thank the staffs from the Central Epidemiologic Laboratory of the RKI and the Laboratory of the Center for Biological Threats and Special Pathogens (ZBS 1) of the RKI and the staff of the National Consultant Laboratory for Coronaviruses, Institute of Virology, of the Charité – Universitätsmedizin Berlin for their analyses. We are also grateful to all participants who took part in this study.

**Funding:** The study was funded by the German Federal Ministry of Health (reference number ZMVI1-2520COR402).

**Conflict of interest**

Dr Víctor M Corman is named together with Euroimmun on a patent application filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing.
Authors’ contributions

TL, CSH, MB, ASR, MS, RH, AG, JH, CK, JA, SH, HW, LHW and LS initiated the study. AHE, SB, TZ, AN, JM, OH, VMC and CD contributed to the acquisition and interpretation of data. All authors including the CoMoLo study group members contributed to aspects of the study design. ASR and RH analysed the data and HKM wrote the first draft manuscript. All authors including the CoMoLo study group members contributed to manuscript conceptualisation, critically revised the manuscript and approved the final version.

References

1. Santos-Hövener C, Busch MA, Koschollek C, Schlaud M, Hoebel J, Hoffmann R, et al. Seropidemiologische Studie zur Verbreitung von SARS-CoV-2 in der Bevölkerung an besonders betroffenen Orten in Deutschland – Studienprotokoll von CORONA-MONITORING lokal. Journal of Health Monitoring. 2020;5(S2):2-18.

2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3):2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045 PMID: 3199287

3. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-19. Nature. 2020;581(7809):265-9. https://doi.org/10.1038/s41586-020-2695-3 PMID: 3223495

4. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107(1):71-6. https://doi.org/10.1093/oxfjournals.aje.a112510 PMID: 623091

5. Oved K, Olmer L, Shemer-Avin Y, Wolf T, Supino-Rosin L, Pragrod G, et al. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subgroup. EClinical Medicine. 2020;100651.

6. Ibarondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann MA, et al. Rapid decay of viral neutralizing antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085-7. https://doi.org/10.1056/NEJMc2025179 PMID: 32706954

7. Seow J, Graham C, Merrick AC, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598-607. https://doi.org/10.1038/s41564-020-00813-8 PMID: 33106674

8. Long QX, Dang HJ, Chu Y, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(3):276-9. https://doi.org/10.1038/s41591-020-00965-6 PMID: 3255424

9. Weis S, Scherag A, Baier M, Kleinboth M, Kamrat T, Kolano S, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study. medRxiv. 2020;2020.07.15.20154122. Available from: https://www.medrxiv.org/content/10.1101/2020.07.15.20154121v1

10. Poethko-Müller C, Prütz F, Buttmann-Schweiger N, Fleibig J, Sarganas G, Seeling S, et al. Studien zur Seroprävalenz von SARS-CoV-2 in Deutschland und international. Journal of Health Monitoring. 2020;5(S4):2-16.

11. Streeck H, Schulze B, Kümmener BM, Richter E, Höller T, Fuhrmann C, et al. Infection fatality rate of SARS-CoV-2 in a super-spread ing event in Germany. Nat Commun. 2020;11(35829). https://doi.org/10.1038/s41467-020-19509-y PMID: 32038867

12. Aziz NA, Corman VM, Echterhoff AKC, Richter A, Schmandke A, Schmidt ML, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany. medRxiv. 2020;2020.08.24.20181206. Available from: https://www.medrxiv.org/content/10.1101/2020.08.24.20181206v1

13. Knabl L, Mitra T, Kimpel J, Roessler A, Volland A, Walser A, et al. High SARS-CoV Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl. medRxiv. 2020;2020.08.20.20178533. Available from: https://www.medrxiv.org/content/10.1101/2020.08.20.20178533v1

14. Percivalle E, Cambi G, Cassaniti J, Nepita EV, Masera R, Ferrara A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill. 2020;25(24). https://doi.org/10.2807/1560-7917.ES.2020.25.24.2001031 PMID: 32583766

15. Chen X, Chen Z, Azman AS, Deng X, Chen X, Lu W, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. medRxiv. 2020;2020.09.11.20192773. Available from: https://www.medrxiv.org/content/10.1101/2020.09.11.20192773v2

16. Guðbjartisson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724-34. https://doi.org/10.1056/NEJMoa2026116 PMID: 32871063

17. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020;2020.03.30.20047365. Available from: https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v2

18. Wang X, Guo X, Xin Q, Pan Y, Li J, Chu Y, et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. medRxiv. 2020;2020.04.15.20065623. Available from: https://www.medrxiv.org/content/10.1101/2020.04.15.20065623v3

19. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al., ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seropidemiological study. Lancet. 2020;396(10250):535-44. https://doi.org/10.1016/S0140-6736(20)31483-5 PMID: 32645347

20. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. 2020;48:23-29.eq. https://doi.org/10.1016/j.amepi.2020.06.004 PMID: 32648546

21. Houllihan CF, Beale R. The complexities of SARS-CoV-2 serology. Lancet Infect Dis. 2020;S1473-3099(20)30678-0. PMID: 32979377

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2020.